US Drug Recall Register

FDA Drug Recalls

11,815 recalls · Class II, newest first

Class II · Moderate risk Terminated

Irinotecan HCL Injection

Reason Defective Container: Customer complaints received of a crimp defect while removing the flip-cap during use.

Hikma Pharmaceuticals USA Inc. NDC 0143-9583-01 D-1309-2020
Class II · Moderate risk Terminated

Irinotecan HCL Injection

Reason Defective Container: Customer complaints received of a crimp defect while removing the flip-cap during use.

Hikma Pharmaceuticals USA Inc. NDC 0143-9701-01 D-1308-2020
Class II · Moderate risk Terminated

Aripiprazole Tablets

Reason Labeling: Label mix up: Bottles labeled as aripiprazole 2 mg, 30 count had aripiprazole 5 mg tablets, 100 count.

Alembic Pharmaceuticals Limited NDC 62332-097-30 D-1341-2020
Class II · Moderate risk Terminated

Nystatin Cream

Reason Subpotent Drug: Out of specification for assay at the 9-month interval for Nystatin Cream, USP.

Crown Laboratories NDC 0316-0221-15 D-1339-2020
Class II · Moderate risk Terminated

Nystatin Cream

Reason Subpotent Drug: Out of specification for assay at the 9-month interval for Nystatin Cream, USP.

Crown Laboratories NDC 0316-0221-30 D-1338-2020
Class II · Moderate risk Terminated

Time-Cap Labs

Reason CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level

Marksans Pharma Limited NDC 49483-623-01 D-1356-2020
Class II · Moderate risk Terminated

metFORMIN HCL ER 500 mg

Reason CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level

PD-Rx Pharmaceuticals, Inc. NDC 72789-009-30 D-1333-2020
Class II · Moderate risk Terminated

metFORMIN HCL ER USP 500 mg

Reason CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level

PD-Rx Pharmaceuticals, Inc. D-1307-2020
Class II · Moderate risk Terminated

Metformin Hydrochloride Extended-Release Tablets

Reason CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level

AVKARE Inc. NDC 50268-531-15 D-1305-2020
Class II · Moderate risk Terminated

Metformin Hydrochloride Extended-Release Tablets

Reason CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level

AVKARE Inc. NDC 42291-611-90 D-1304-2020
Class II · Moderate risk Terminated

Walker Hand Sanitizer

Reason Incorrect/Undeclared Excipients: Notification received from Health Canada that DA-2I Ethanol is a type not an approved for use in Hand Sanitizer.

Walker Emulsions INC NDC 74940-0415-1 D-1417-2020
Class II · Moderate risk Terminated

Walker Emulsions Hand Sanitizer

Reason Incorrect/Undeclared Excipients: Notification received from Health Canada that DA-2I Ethanol is a type not an approved for use in Hand Sanitizer.

Walker Emulsions INC NDC 74940-0415-1 D-1416-2020
Class II · Moderate risk Terminated

Soft Whisper by Powerstick Dandruff Shampoo

Reason cGMP Deviations: Soft Whisper Dandruff Shampoo was produced with water that failed USP specifications.

A.P. Deauville, LLC NDC 42913-020-00 D-1337-2020
Class II · Moderate risk Terminated

Metformin Hydrochloride Extended-Release Tablets

Reason CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level

Teva Pharmaceuticals USA NDC 62037-577-01 D-1332-2020
Class II · Moderate risk Terminated

Metformin Hydrochloride Extended - Release Tablets

Reason CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level

Teva Pharmaceuticals USA NDC 62037-571-01 D-1331-2020
Class II · Moderate risk Terminated

Handese Advanced Instant Hand Sanitizer

Reason Subpotent Drug: Product was found to be subpotent. Product also has high pH levels

World Event Promotions, LLC D-1411-2020
Class II · Moderate risk Terminated

Unasyn

Reason Presence of Particulate Matter: particulate matter identified after reconstitution.

Pfizer Inc. NDC 0049-0013-81 D-1306-2020
Class II · Moderate risk Terminated

Gaviscon Liquid Antacid Extra Strength

Reason Labeling: Label lacks warning - Magnesium safety warning is not present on the Gaviscon bottle label.

Glaxosmithkline Consumer Healthcare Holdings NDC 0135-0095-41 D-1325-2020
Class II · Moderate risk Terminated

Gaviscon Regular Strength Liquid Antacid Cool Mint

Reason Labeling: Label lacks warning - Magnesium safety warning is not present on the Gaviscon bottle label.

Glaxosmithkline Consumer Healthcare Holdings NDC 0135-0094-41 D-1323-2020
Class II · Moderate risk Terminated

Gaviscon Regular Strength Liquid Antacid Cool Mint

Reason Labeling: Label lacks warning - Magnesium safety warning is not present on the Gaviscon bottle label.

Glaxosmithkline Consumer Healthcare Holdings NDC 0135-0094-42 D-1322-2020
Class II · Moderate risk Terminated

oxyTOCIN 30 Units/500 mL

Reason Subpotent drug - Product did not contain drug.

QuVa Pharma, Inc. NDC 70092-1068-07 D-1302-2020
Class II · Moderate risk Terminated

Lisinopril Tablets

Reason Product Mix Up: Lisinopril 10 mg tablets were found in Lisinopril 5 mg 1000-count bottle.

Lupin Pharmaceuticals Inc. NDC 68180-513-03 D-1290-2020
Class II · Moderate risk Terminated

Doxycycline Hyclate Tablets

Reason Failed Dissolution Specification: The dissolution test at the 24 month time point (end of shelf life) yielded an out-of-specification result.

The Harvard Drug Group NDC 0904-0430-04 D-1288-2020